SharpyOzempic Vision Loss (NAION): What the New Studies Mean
Ozempic vision loss is a real but rare concern: a study in Annals of Internal Medicine, publicized by Rutgers in October 2026, found about 3 to 4 extra cases of ischemic optic neuropathy per 10,000 people over 18 months after starting semaglutide or tirzepatide, and it did not prove the drugs cause it. Europe lists the eye condition NAION as a "very rare" semaglutide side effect (up to 1 in 10,000), while US labels do not list it yet. Do not stop your medication on your own; get same-day eye care for sudden vision loss, and keep building muscle and protein habits with Sharpy.
Can Ozempic cause vision loss? This week the question is back in the news. A large US study found a small rise in a rare optic nerve problem in people who started GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound. The extra risk was about 3 to 4 cases per 10,000 people over 18 months. The study did not prove the drugs cause it. The condition, called NAION, can cause sudden and lasting vision loss in one eye, so it is worth knowing the signs.
Here is what is new, how rare it is, and what to do.
What is NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain words, it is a stroke of the optic nerve, the cable that carries pictures from your eye to your brain. Blood flow to the front of the nerve drops, and part of the nerve is damaged.
- It usually hits one eye.
- It is usually painless.
- It often takes out part of your vision, like the top or bottom half, rather than all of it.
- More than 80% of ischemic optic neuropathy cases are this type, according to Rutgers.
Known risk factors include diabetes (with or without a GLP-1), low blood pressure at night, and a small, crowded optic nerve head that an eye doctor can see on an exam.
What the October 2026 Ozempic vision loss study found
Researchers at Rutgers, led by Chintan Dave, published the study in Annals of Internal Medicine (volume 179, issue 9). It looked at US adults aged 18 to 65 with type 2 diabetes who had just started a diabetes medicine. People who started a GLP-1, including semaglutide and tirzepatide, were compared with people who started other diabetes drugs.
The main points:
- GLP-1 use was tied to a modest increase in ischemic optic neuropathy.
- The extra risk was about 3 to 4 cases per 10,000 people over 18 months.
- Most cases were in men, and in people aged 50 to 65.
- The authors say it does not prove the drugs damage the nerve. People who get GLP-1s may differ in health from people who get other drugs.
A second study: the other eye
On October 6, 2026, the American Academy of Ophthalmology shared a study presented at its yearly meeting. It used health records from Epic Cosmos and looked at people who had already had NAION in one eye. About 15% of NAION patients get it in the second eye within five years.
| Group | People in study | Second-eye cases that came within 6 months |
|---|---|---|
| Taking a GLP-1 | about 1,440 | 56.8% |
| Not taking a GLP-1 | about 20,700 | 40.6% |
So in GLP-1 users, when the second eye was hit, it tended to happen sooner. But the GLP-1 group also had higher A1C (by 1.0 to 1.4 points), which means worse diabetes could explain some or all of the gap. The data were pooled, not patient by patient, so again this is a link, not proof.
How rare is Ozempic vision loss?
Here is how different sources size the risk.
| Source | What it says |
|---|---|
| Annals of Internal Medicine study (2026) | About 3 to 4 extra cases per 10,000 people over 18 months on GLP-1s |
| European Medicines Agency safety committee (June 2025) | NAION is a "very rare" semaglutide side effect, up to 1 in 10,000 people; about 1 extra case per 10,000 person-years in type 2 diabetes |
| UK MHRA (February 2026) | Sudden vision loss on semaglutide should be urgently referred to an eye specialist |
| US labels on DailyMed (Ozempic July 2026, Wegovy June 2026, Zepbound September 2026) | NAION is not listed; diabetic retinopathy warning is |
Put simply, if 10,000 people take a GLP-1 for a year or more, a few extra might get NAION. For most people, the heart, blood sugar and weight benefits are much bigger. That trade-off is personal, though, and belongs to you and your doctor.
What the US labels say about eyes
The US labels warn about diabetic retinopathy, a different eye disease. In a 2-year trial in people with type 2 diabetes, retinopathy complications happened in 3.0% of people on Ozempic and 1.8% on placebo. The jump was bigger in people who already had retinopathy (8.2% vs 5.2%). The label says a fast drop in blood sugar can make retinopathy worse for a while, and people with a history of it should be watched.
That is one reason a yearly eye exam is part of the plan in our GLP-1 and type 2 diabetes guide.
Ozempic vision loss symptoms: when to get help
Go to an eye doctor or emergency room the same day if you notice:
- Sudden loss of vision in one eye, even if it does not hurt
- A new dark patch, shadow or blind spot
- Half of your view (top or bottom) looking dim or missing
- Colors looking washed out in one eye
Tell them you take a GLP-1 and which one. Mild blurry vision that comes and goes in the first weeks can happen when blood sugar shifts, but you should not guess. Let a doctor check.
Should you stop Ozempic, Wegovy or Mounjaro?
Not on your own. The American Academy of Ophthalmology says patients should not stop these medicines because of this research. Europe advises stopping semaglutide only if NAION is confirmed. Talk with your prescriber if:
- You have had NAION or another optic nerve problem before
- You have diabetic retinopathy
- You have been told you have a "crowded" optic nerve
Your doctor may suggest an eye exam before you start or keep going. If you are comparing drugs, our GLP-1 medication comparison and Wegovy vs Ozempic guide cover the basics.
The part you can control
You cannot control a rare eye event. You can control the habits that make your GLP-1 work for you: steady protein, regular strength training and honest tracking. Fast weight loss on these drugs can take muscle with it, and muscle is what keeps you strong and your metabolism healthy. Sharpy gives you one protein target, one 20-minute workout and a daily Shape Score, so you keep the muscle while the fat comes off.
If you are new to the shot, our first month on Ozempic guide walks through each week. And keep your regular eye exams on the calendar, especially if you have diabetes.
Bottom line
New studies link GLP-1 drugs to a small rise in a rare optic nerve stroke called NAION, about 3 to 4 extra cases per 10,000 people over 18 months in the latest one. Cause is not proven. Know the warning signs, get same-day care for sudden vision loss, and talk to your prescriber before changing anything. Then keep doing the daily work that protects your body, and let Sharpy keep score.
Sources
- Researchers find small increased risk of sudden vision loss associated with GLP-1 medications, Rutgers
- Ozempic and Wegovy linked to rare risk of sudden vision loss, ScienceDaily, October 2026 (Annals of Internal Medicine 2026;179(9))
- GLP-1 drugs linked to faster vision loss in the second eye, American Academy of Ophthalmology, October 6, 2026
- PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines, European Medicines Agency
- Semaglutide: risk of NAION, MHRA Drug Safety Update
- Ozempic (semaglutide) prescribing information, DailyMed
- What GLP-1 users should know about the potential risk of a rare type of vision loss, ABC News, September 2026
Questions people ask
Does Ozempic cause vision loss?
It has not been proven. Several large studies link semaglutide (Ozempic, Wegovy) and other GLP-1 drugs to a small rise in NAION, a stroke of the optic nerve. These studies show an association, not cause and effect. Europe's drug regulator decided in June 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people.
What are the symptoms of Ozempic vision loss?
NAION usually causes sudden, painless vision loss in one eye. People describe blurriness, dimming, or a dark patch or blind spot, often in the top or bottom half of what they see. It is not the same as the mild blurry vision some people notice when blood sugar changes. Sudden vision loss of any kind needs an eye doctor the same day.
Is Ozempic vision loss temporary?
NAION is often permanent. About one third of people get some vision back, mostly within six months, but some loss usually remains. There is no proven treatment to reverse it, which is why fast checkups and talking to your prescriber matter.
Is there an FDA warning about Ozempic and vision loss?
As of October 19, 2026, the US labels for Ozempic, Wegovy and Zepbound on DailyMed do not list NAION. They do warn about diabetic retinopathy complications in people with type 2 diabetes. ABC News reported in September 2026 that the FDA is reviewing the possible signal through its Sentinel system. Europe, the UK and Australia have added NAION to their product information.
Does Mounjaro or Zepbound cause vision loss too?
The new Annals of Internal Medicine study included both semaglutide and tirzepatide (Mounjaro, Zepbound) and found the small increase across GLP-1 drugs as a group. The European "very rare" listing is for semaglutide products. Tirzepatide has not been studied as much for this question.
Should I stop Ozempic because of the vision loss risk?
Do not stop on your own. The American Academy of Ophthalmology says people should not stop these drugs because of the studies. If you have had NAION before, or have other eye disease, talk with your prescriber and eye doctor about your own risk before you start or continue.